Stem cell biotech Neuroplast enrolls first patient in Phase

Neuro-Cells treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following traumaThe randomized, placebo-controlled, international multi-center

Related Keywords

United States , Denmark , Netherlands , Spain , Geleen , Limburg , Amsterdam , Noord Holland , Spanish , Danish , Dutch , Kostenloser Wertpapierhandel , Erik Wolters , Prnewswire Neuroplast , Antonio Oliviero , Medicamentosy Productos Sanitarios , Brightlands Agrifood Fund , National Videnskabsetisk Komit , Netherlands Enterprise Agency , Danish Medicines Agency , Dutch Ministry Of Economic Affairs , Traumatic Spinal Cord Injury , Traumatic Brain Injury , Frontotemporal Dementia , Hospital Nacional De Parapl , Principal Investigators Antonio Oliviero , Hospital Parapl , Principal Investigator , Spinal Cord Injury , Spinal Cord , Agencia Espanola De Medicamentos , Productos Sanitarios , Danish Medicines , Johannes De Munter , Lumana Invest , Brightlands Venture Partners , Netherlands Enterprise , Brightlands Chemelot Campus , Hospital De Parapl , Nacional De Parapl , Venture Partners , Chemelot Ventures , Dutch Ministry , Economic Affairs , Spring Lifesciences Communication , System , Fell , Biotech , Neuroplast , Enrolls , First , Patient , Hase , Linical , Trial , Ransformative , Euro , Cells , Treatment , Traumatic , Espinal , Ford , Injury ,